EP2185559A1 — Crystalline form of a dihydropteridione derivative
Assigned to Boehringer Ingelheim International GmbH · Expires 2010-05-19 · 16y expired
What this patent protects
The present invention relates to a crystalline form a dihydropteridione derivative, namely a crystalline form of the free base N- [trans-4- [4- (cyclopropylmethyl) - 1-piperazinyl] cyclohexyl] -4- [[(7R) -7-ethyl-5, 6. 7, 8 - tetrahydro - 5 -methyl - 8 - (1 -methylethyl) - 6 - ox…
USPTO Abstract
The present invention relates to a crystalline form a dihydropteridione derivative, namely a crystalline form of the free base N- [trans-4- [4- (cyclopropylmethyl) - 1-piperazinyl] cyclohexyl] -4- [[(7R) -7-ethyl-5, 6. 7, 8 - tetrahydro - 5 -methyl - 8 - (1 -methylethyl) - 6 - oxo - 2 - pteridinyl] amino] - 3 -methoxy -benz amide of structure (I), to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.
Drugs covered by this patent
- Palbociclib (palbociclib) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.